Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
CRANBURY, N.J., Oct. 25, 2017 -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, November 8, 2017 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2017.
The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 5995789.
A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download, and install any necessary software.
A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on November 8, 2017. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 5995789.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
CONTACTS:
Investors/Media:
Amicus Therapeutics
Sara Pellegrino, IRC
Senior Director, Investor Relations
[email protected]
(609) 662-5044
Media:
W2O Group
Jennifer Paganelli
Media Relations
[email protected]
(347) 658-8290
FOLD–G
